Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00227357
Status:
COMPLETED
Last Update Posted:
2010-06-07
First Post:
2005-09-27
Brief Title:
The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration
Sponsor:
Ruth M Rothstein CORE Center
Organization:
Ruth M Rothstein CORE Center
Study Overview
Official Title:
SPNS - An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BUP
Brief Summary:
The goal of this study is to develop and evaluate an innovative model of care to better serve patients who are both HIV-infected and opioid-dependent
Detailed Description:
Hypothesis HIV opioid dependent patients provided agonist therapy at the site of their primary care will have better retention utilization of services health social and quality of care measures and psychiatric treatment outcomes
The Buprenorphine Project is an examination of two methods of service delivery The purpose of this study is to assess the feasibility cost and effectiveness of an intervention designed to integrate buprenorphine treatment for opioid dependence into HIV primary care at the CORE Center For this project we will provide buprenorphine to 60 opioid dependent patients at any one time and will compare this on-site treatment group to 60 opioid dependent HIV patients who select off-site methadone or no agonist treatment at the time of enrollment
The Buprenorphine Project is an examination of two methods of service delivery The purpose of this study is to assess the feasibility cost and effectiveness of an intervention designed to integrate buprenorphine treatment for opioid dependence into HIV primary care at the CORE Center For this project we will provide buprenorphine to 60 opioid dependent patients at any one time and will compare this on-site treatment group to 60 opioid dependent HIV patients who select off-site methadone or no agonist treatment at the time of enrollment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None